Akshar Pharma

Eltrombo 25 mg (Eltrombopag Olamine) is a prescribed medication specifically designed to address low platelet count levels resulting from chronic immune thrombocytopenic purpura (ITP) or chronic hepatitis C virus (HCV) infection. These conditions pose a risk of bleeding, and Eltrombo 25 mg aids in managing them effectively. It is also utilized in the treatment of severe aplastic anemia by stimulating bone marrow cell production and increasing platelet levels, thus minimizing bleeding risks.

In patients with deleterious or suspected deleterious gBRCAm, human epidermal growth factor receptor 2 (HER2)-negative metastatic breast cancer who have previously been treated with chemotherapy in the neoadjuvant, adjuvant or metastatic setting. Patients with hormone receptor (HR)-positive breast cancer should have been treated with a prior endocrine therapy or be considered inappropriate for endocrine treatment.

Indications for use PALBOCICLIB is indicated for the treatment of hormone receptor (HR)-positive, human epidermal growth factor 2 (HER2)-negative, locally advanced or metastatic breast cancer: – in combination with an aromatase inhibitor; – in combination with fulvestrant in women previously receiving endocrine therapy. In pre-or perimenopausal women, endocrine therapy should be combined with aluteinization.  Hormone Releasing Hormone (LHRH) agonists.

Pazopanib 400 mg is a potent muti-target tyrosine kinase inhibitor (TKI) of vascular endothelial growth factor receptors (VEGFR) -1 ,-2, and -3, platelet- derived growth factor (PDGFR) -a, and -b, and stem cell factor receptor (c-KIT), with IC 50 values of 10, 30, 47, 71, 84 and 74 nM,  respectively.

• Tumor Suppression: Temzokey 100 capsules contain Temozolomide, a potent chemotherapy agent that works by disrupting the growth and spread of cancer cells in the brain, offering hope for improved outcomes and extended survival in patients with glioblastoma multiforme and other malignant brain tumors.
• Clinical Excellence: Backed by extensive clinical research and real-world experience, Temzokey 100 has demonstrated its efficacy in improving patient outcomes and quality of life.
• Quality Assurance: Unnati Pharmax maintains strict quality control standards to ensure that every Temzokey 100 capsule meets the highest standards of purity and potency, providing peace of mind for patients and healthcare providers alike.
• Patient-Centric Design: Designed with patient comfort and convenience in mind, Temzokey 100 capsules are easy to swallow and incorporate into daily treatment regimens, empowering patients to take control of their health.

• Tumor Regression: Temzokey 250 capsules work to shrink tumors and slow their growth, helping to improve symptoms and prolong survival in patients with glioblastoma multiforme and other malignant brain tumors.
• Symptom Relief: Experience relief from symptoms such as headaches, seizures, and cognitive decline, leading to an improved quality of life and enhanced well-being.
• Personalized Treatment: With individualized dosing options, Temzokey 250 allows for tailored treatment plans to meet the unique needs of each patient, optimizing therapeutic outcomes.

Thalidomide is primarily indicated for
the acute treatment of the cutaneous manifestances of
moderate to severe Erythema Nodosum Leprosum (ENL).
• Thalidomide is also indicated in the treatment of
Multiple myeloma. • Partially designed orphan drug for
use in the treatment or prevention of unresponsive
chronic graft-versus-host disease, discoid lupus
erythematosus, and Behcet’s syndrome and for treatment
of refractor oropharyngeal ulceration and washing in
AIDS patients. Thalidomide has the potential for
treatment of breast cancer, Kaposi Sarcoma and
glioblastoma also.

ANZAKAST is used in treatment of early breast cancer in postmenopausal women. ANZAKAST is also used for Treatment of advanced breast cancer in postmenopausal women.

·         CAPEKAST is indicated as first-line treatment of patients with metastatic colorectal carcinoma  and also indicated as a single agent for adjuvant treatment in patients with Dukes c colon cancer.

·         CAPEKAST in combination with docetaxel is indicated for the treatment of patients with for  metastatic breast cancer.

Lenalidomide, sold under the trade name Lenakast among others, is a medication used to treat multiple myeloma (MM) and myelodysplastic syndromes (MDS). For MM it is used after at least one other treatment and generally together with dexamethasone. It is taken by mouth.

The dose may need to be adjusted in people with kidney problems.It has a chemical structure similar to thalidomide but has a different mechanism of action.

·         LENVAKAST is indicated for The treatment of patients with locally recurrent or metastatic, progressive, radioactive iodine-refractory diflerentiated thyroid cancer (DTc).

·         LENVAKAST is indicated for the first-line treatment of patients with unresectable hepatocellular carcinoma.

·         LENVAKAST is also indicated for Endometrial carcinom.

COMPOSITION: Each film coated tablet contains: Letrozole 2.5mg

INDICATION: LETRAKAST is indicated for use in the treatment of advanced breast cancer resistant to antioestrogen therapy in post-menopausal women.

PACKING: 10×10 Tablets

COMPOSITION: Each tablet contains Sorafenib 200 mg

INDICATION: SORAFEKAST is indicated for

·         Hepatocellular cell carcinoma that cannot be removed by surgery (Liver cancer)

·         Renal cell carcinoma (Kidney cancer)

·         Difierentiated Thyroid carcinoma (Thyroid cancer)

Cytarabine Injection in combination with
other approved anticancer drugs is indicated for remission
induction in acute non-lymphocytic leukemia of adults and
pediatric patients. It has also been found useful in the
treatment of acute lymphocytic leukemia and the blast
phase of chronic myelocytic leukemia. Intrathecal
administration of Cytarabine Injection is indicated in the
prophylaxis and treatment of meningeal leukemia.

Cytarabine Injection in combination with
other approved anticancer drugs is indicated for remission
induction in acute non-lymphocytic leukemia of adults and
pediatric patients. It has also been found useful in the
treatment of acute lymphocytic leukemia and the blast
phase of chronic myelocytic leukemia. Intrathecal
administration of Cytarabine Injection is indicated in the
prophylaxis and treatment of meningeal leukemia.

Dacarbazine Injection IP 200 mg is indicated in
the treatment of metastatic malignant melanoma. In addition,
Dacarbazine Injection IP 200 mg is also indicated for Hodgkin’s
disease as a secondary – line – therapy when used in
combination with other effective agents.

Etoposide Injection is indicated in
the management of the following neoplasms: Refractory Testicular
Tumors: Etoposide Injection in combination therapy with other
approved chemotherapeutic agents in patients with refractory
testicular tumors who have already received appropriate surgical,
chemotherapeutic, and radiotherapeutic therapy. Small Cell Lung
Cancer: Etoposide Injection and/or capsules in combination with
other approved chemotherapeutic agents as first line treatment in
patients with small cell lung cancer.

• Apragem in combination with carboplatin is indicated for the treatment of patients with
  advanced ovarian cancer that has relapsed at least 6 months after completion of platinum-based
  therapy.
• Apragem in combination with paclitaxel is indicated for the first-line treatment of patients with metastatic breast cancer after failure of prior anthracycline- containing adjuvant chemotherapy, unless anthracyclineswere clinically contraindicated

·         Metastatic Testicular cancer: In established combination therapy with other approvaed chemotherapeutic agents in patients with metastic surgical and/or radio therapeutic procedures.

·         Metastatic Ovarian cancer: In established combination therapy with other approved chemotherapeutic agents cisplatin Injection is used in patients with metastatic overian tumors who have already received appropriate surgical and/or radio therapeutic procedures.

·         Docetaxel is indicated for the treatment of patients with locally advanced or metastatic breast cancer after failure of prior chemotherapy.

·         Docetaxel in combination with doxorubicin and cyclophosphamide is indicated for the adjuvant treatment of patients with operable node-positive breast cancer.

·         Docetaxel is also indicated for the treatment of patients with locally advanced or metastatic non- small cell lung cancer after failure of prior platinum- based chemotherapy.

·         Docetaxel is indicated for the treatment of patients with locally advanced or metastatic breast cancer after failure of prior chemotherapy.

·         Docetaxel in combination with doxorubicin and cyclophosphamide is indicated for the adjuvant treatment of patients with operable node-positive breast cancer.

·         Docetaxel is also indicated for the treatment of patients with locally advanced or metastatic non- small cell lung cancer after failure of prior platinum- based chemotherapy.